Breaking News Instant updates and real-time market news.

MU

Micron

$32.62

-0.7 (-2.10%)

, CNC

Centene

$57.72

0.73 (1.28%)

07:35
06/03/19
06/03
07:35
06/03/19
07:35

Unusual call flow in option market yesterday

Notable call activity was cited Friday in Micron (MU), Centene (CNC), Exxon Mobil (XOM), Mylan (MYL), Marathon Petroleum (MPC), Avaya Holdings (AVYA), Emerson (EMR), KeyCorp (KEY), Barnes & Noble (BKS), and CymaBay (CBAY).

MU

Micron

$32.62

-0.7 (-2.10%)

CNC

Centene

$57.72

0.73 (1.28%)

XOM

Exxon Mobil

$70.75

-1.24 (-1.72%)

MYL

Mylan

$16.79

-0.42 (-2.44%)

MPC

Marathon Petroleum

$46.01

-1.09 (-2.31%)

AVYA

Avaya

$12.58

0.41 (3.37%)

EMR

Emerson

$60.25

-0.95 (-1.55%)

KEY

KeyCorp

$15.97

-0.34 (-2.08%)

BKS

Barnes & Noble

$4.38

0.08 (1.86%)

CBAY

CymaBay

$12.09

0.19 (1.60%)

  • 04

    Jun

  • 12

    Jun

  • 14

    Jun

  • 24

    Jun

  • 25

    Jun

  • 23

    Jul

  • 23

    Jul

  • 06

    Aug

  • 22

    Aug

  • 29

    Aug

MU Micron
$32.62

-0.7 (-2.10%)

05/31/19
DBAB
05/31/19
NO CHANGE
Target $45
DBAB
Buy
Micron estimates lowered on Huawei, pricing weakness at Deutsche Bank
To reflect the recent stop-shipment to Huawei along with incremental memory pricing weakness, Deutsche Bank analyst Sidney Ho lowered his 2019 earnings per share estimate for Micron Technology to $3.30 from $4.40 and 2020 estimate to $3.75 from $4.70. While memory suppliers have taken utilization actions in an attempt to bring the memory market back to supply/demand balance, the Huawei ban will likely delay the recovery and potentially lead to near term share shift toward Micron's competitors, Ho tells investors in a research note. The analyst currently anticipates some resolution for the Huawei situation will be reached by the end of 2019. If the issues linger into 2020, estimates for Micron have additional downside risk, adds Ho. However, he believes downside risk is limited in shares of Micron and that the risk/reward is attractive. Ho keeps a Buy rating on the name.
05/31/19
STFL
05/31/19
NO CHANGE
Target $54
STFL
Buy
Micron price target lowered to $54 from $60 at Stifel
Stifel analyst Kevin Cassidy lowered his estimates for Micron Technology to reflect the "many uncertainties" associated with the Huawei ban as well as updated memory pricing. Shipments into China accounted for 32% of Micron's fiscal 2018 revenue and Huawei accounts for 13% of the company's revenue, Cassidy tells investors in a research note, citing management. Further, based on recent inSpectrum data, the analyst now estimates DRAM selling prices will decline 23% quarter-over-quarter in the May quarter, compared to his prior estimate of down 20%. For NAND, Cassidy estimates a 14% quarter-over-quarter average selling price decline compared to his previous estimate of down 5%. As a result, he cut his May quarter earnings per share estimate for Micron to 72c from 85c and revenue estimate to $4.56B from $4.79B. He also reduced his fiscal 2020 earnings estimate to $6.00 from $6.75 and revenue estimate to $21.475B from $21.85B. Cassidy also dropped his price target for Micron shares to $54 from $60 while keeping a Buy rating on the name.
05/23/19
CLVD
05/23/19
NO CHANGE
CLVD
Micron revenue, EPS estimates lowered at Cleveland Research
Cleveland Research analyst Chandler Converse lowered his 2019 and 2020 revenue and EPS estimates for Micron on softer end demand and channel work that points to some push-out in the timing of a market turn in DRAM and NAND pricing.
06/03/19
NOMU
06/03/19
NO CHANGE
Target $32
NOMU
Neutral
Micron price target lowered to $32 from $45 at Nomura Instinet
Nomura Instinet analyst David Wong lowered his price target for Micron Technology to $32 from $45 while maintaining a Neutral rating on the shares. The analyst believes the global memory industry, and Micron, will grow at a rate similar to the overall semiconductor industry, which he estimates at 7%-9% from 2020 to 2025. In recent weeks, DRAM spot prices have continued to fall, as have NAND TLC spot prices, Wong tells investors in a research note. Further, he believes the U.S. action against Huawei and "various continuing international trade tensions create significant uncertainty" and risk to his earlier hope that there might be some stabilizing in memory through 2019. As a result, Wong lowered his 2020 earnings per share estimate for Micron to $2.47 from $3.30.
CNC Centene
$57.72

0.73 (1.28%)

06/03/19
BMOC
06/03/19
DOWNGRADE
Target $304
BMOC
Market Perform
WellCare downgraded to Market Perform from Outperform at BMO Capital
BMO Capital analyst Matt Borsch downgraded WellCare Health Plans (WCG) to Market Perform from Outperform with an unchanged price target of $304. The analyst sees Centene (CNC) as the better stock to own ahead of the pending merger. There is also the possibility of deal failure, which would leave a standalone investment in WellCare that would probably include less takeout premium than prevailed pre-merger, Borsch tells investors in a research note.
05/10/19
05/10/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. 3D Systems (DDD) upgraded to Neutral from Underweight at JPMorgan with analyst Paul Coster noting the stock is down 25% this week after posting "lackluster" Q1 results. 2. Jones Lang LaSalle (JLL) upgraded to Buy from Neutral at Goldman Sachs with analyst Andrew Rosivach saying the company's earnings declined in Q1 due to tough comps, but this should reverse quickly. 3. Ford (F) upgraded to Buy from Neutral at BofA/Merrill with analyst John Murphy stating the company's earnings are starting to hit a "sustainable inflection" due to favorable product cadence in the North America market and its restructuring efforts. 4. Whirlpool (WHR) upgraded to Buy from Neutral at Longbow with analyst David MacGregor seeing earnings upside from better than expected North American margin performance, a "gradually improving" environment in the EMEA and a favorable cyclical turn in Latin America. 5. Anthem (ANTM), Centene (CNC), and UnitedHealth (UNH) upgraded to Buy from Neutral at Citi with analyst Ralph Giacobbe the magnitude of the selloff in managed care stocks on fears of Medicare for All has been "extreme and overdone". This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/10/19
05/10/19
UPGRADE

Citi upgrades Anthem, Centene, UnitedHealth to Buy after 'extreme' selloff
Citi analyst Ralph Giacobbe upgraded Anthem (ANTM), Centene (CNC), and UnitedHealth (UNH) to Buy from Neutral while maintaining Buy ratings on Cigna (CI) and Humana (HUM). The magnitude of the selloff in managed care stocks on fears of Medicare for All has been "extreme and overdone," Giacobbe tells investors in a research note. The analyst sees favorable risk/rewards in the sector and does not subscribe to the view of a continued "overhang" and "uncertainty." Instead, Giacobbe expects a share recovery as "more realistic views prevail and investors become more numb to the low-likelihood headlines and political rhetoric of single payor."
05/16/19
COWN
05/16/19
NO CHANGE
COWN
Move lower in managed care stocks appears overdone, says Cowen
Cowen analyst Charles Rhyee lowered his target multiple for the managed care group slightly from recent historical levels, but said he believes the recent weakness in the space on concerns around "Medicare for All," the rebate rule and the Texas ACA decision appears overdone. The discount for managed care stocks relative to the broader market has risen to a multi-year high, but he argues that underlying market fundamentals are stronger than in the pre-ACA era and Rhyee contends that there is "still plenty of growth left" in the managed care space, particularly in government-sponsored business. Stocks in the group include Anthem (ANTM), Cigna (CI), Centene (CNC), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).
XOM Exxon Mobil
$70.75

-1.24 (-1.72%)

04/08/19
TUDR
04/08/19
INITIATION
TUDR
Hold
Exxon Mobil initiated with a Hold at Tudor Pickering
05/13/19
HSBC
05/13/19
DOWNGRADE
HSBC
Hold
Exxon Mobil downgraded to Hold from Buy at HSBC
05/13/19
HSBC
05/13/19
UPGRADE
HSBC
Buy
Royal Dutch Shell upgraded to Buy from Hold at HSBC
HSBC analyst Gordon Gray upgraded Royal Dutch Shell (RDS.A) to Buy from Hold. The analyst believes the global integrated oil sector is attractive following the recent selloff in the shares. With free cash break-evens in the low-$50s per barrel oil price, the majors are positioned for a period of sustained excess free cash flow and strong cash distributions, Gray tells investors in a research note. Deutsche Bank this morning also upgraded Royal Dutch Shell to Buy. Gray coupled his upgrade with a downgrade of Exxon Mobil (XOM) to Hold from Buy. He says Exxon's cash generation has been relatively weak.
05/15/19
GSCO
05/15/19
UPGRADE
Target $144
GSCO
Conviction Buy
Chevron upgraded to Conviction Buy from Buy at Goldman Sachs
Goldman Sachs analyst Neil Mehta reinstated a rating on Chevron (CVX) at Buy and added the stock to the firm's Americas Conviction List, stating that Chevron's cash flow profile has positively inflected with the production contribution and capital spending roll-off from the startup of both the Gorgon and Wheatstone LNG projects. Chevron is demonstrating capital discipline, as demonstrated by its decision not to make a counterproposal to Occidental Petroleum's (OXY) offer for Anadarko (APC), and it has a lower capital spending growth rate and a higher production growth rate through 2023 than its closest peer, Exxon (XOM), said Mehta. The analyst has a $144 price target on Chevron shares.
MYL Mylan
$16.79

-0.42 (-2.44%)

05/29/19
WELS
05/29/19
NO CHANGE
Target $188
WELS
Outperform
Allergan selloff on opioid concerns an overreaction, says Wells Fargo
Wells Fargo analyst David Maris attributes the 5% selloff today in shares of Allergan (AGN) to heightened fears of opioid liability risks in the sector. Maris spoke to Allergan's investor relations team, which noted the company is fully indemnified regarding legacy Actavis generics issues. Further, Allergan has very little exposure to branded opioid sales, as they represent a very small percentage of the company's branded business, Maris tells investors in a research note. He believes the decline in Allergan shares is an overreaction to the negative headlines related to opioid-based litigation facing a number of specialty pharma companies such as Teva (TEVA), Mylan (MYL), and Mallinckrodt (MNK). Maris calls the selloff overdone and recommends buying shares of Allergan. He keeps an Outperform rating on the name with a $188 price target.
05/28/19
UBSW
05/28/19
NO CHANGE
Target $23
UBSW
Neutral
Mylan price target lowered to $23 from $31 at UBS
UBS analyst Navin Jacob lowered his price target on Mylan to $23 and kept his Neutral rating, saying the recent allegations of price fixing create "some leverage concerns". The analyst says he is troubled by the uncertainty and the scope of the path of litigation over the longer term, while noting that in the near term, Q1 results left "unanswered questions" about the company's execution issues. Jacob's new price target reflects his reduced forward earnings multiple assumption of 6.0-times, down from 7.5-times in his prior view.
05/15/19
WELS
05/15/19
NO CHANGE
WELS
Lawsuit creates overhang for Teva, Mylan, says Wells Fargo
Wells Fargo analyst David Maris continues to be cautious on Teva (TEVA) and Mylan (MYL) following the price fixing lawsuit against generic companies, and said that the lack of criminal charges "does not take away the financial overhang of the suit." The analyst added that this suit may stop "opportunistic price increases in generics." He remains on the sidelines on both Teva and Mylan, both of which he has Market Perform ratings on.
05/30/19
WELS
05/30/19
NO CHANGE
WELS
U.S. generic data continues to show challenging environment, says Wells Fargo
Wells Fargo analyst David Maris says that according to April IQVIA data, Teva (TEVA) U.S. generic sales were down 19% in April year over year, while brands sales were down 15%. Additionally, according to IQVIA data, Teva recently ceded its second place U.S. prescription market share place to competitor Eli Lilly (LLY) for its migraine drug, Ajovy, he points out. For Mylan (MYL), Maris says the monthly trends also paint a negative picture, with IQVIA U.S. generic sales in April down 36%. Nonetheless, the analyst believes Teva and Mylan shares seem to be reflecting an "aggressively negative outlook" given the current earnings multiples, and setting aside the worst-case outcomes in the opioid and price fixing cases, these may be at or nearing attractive valuations. However, for now, he remains on the sidelines, and within generics, continues to recommend Outperform-rated Amphastar (AMPH).
MPC Marathon Petroleum
$46.01

-1.09 (-2.31%)

05/13/19
FBCO
05/13/19
NO CHANGE
Target $80
FBCO
Outperform
Marathon Petroleum price target lowered to $80 from $95 at Credit Suisse
Credit Suisse analyst Manav Gupta lowered his price target for Marathon Petroleum to $80 from $95 to reflect Q2 throughput and opex guidance provided by the company on its Q1 earnings call, which was significantly weaker than he expected. The analyst reiterates an Outperform rating on the shares.
05/10/19
COWN
05/10/19
DOWNGRADE
COWN
Market Perform
Marathon Petroleum downgraded to Market Perform from Outperform at Cowen
Cowen analyst Jason Gabelman downgraded Marathon Petroleum to Market Perform from Outperform.
05/09/19
WELS
05/09/19
NO CHANGE
Target $90
WELS
Outperform
Marathon Petroleum price target lowered to $90 from $96 at Wells Fargo
Wells Fargo removed Marathon Petroleum as a Top Pick in the refining sector and lowered its price target on the shares to $90 from $96, but kept an Outperform rating on the name. The firm cited Marathon's quarterly results and the impact of Q2 guidance on throughputs and opex.
04/29/19
BOFA
04/29/19
UPGRADE
BOFA
Buy
BofA less worried on U.S. independent refiners, upgrades Phillips 66, two others
BofA Merrill Lynch analyst Doug Leggate said he believes the worst has passed for the U.S. independent refiners and that he now has a less cautious sector view, upgrading HollyFrontier (HFC) and PBF Energy (PBF) to Neutral and raising his rating on Phillips 66 (PSX) to Buy, stating that he sees all the stocks trading below mid-cycle valuations. He noted that his top rated ideas in the group remain Marathon Petrol (MPC) and Valero (VLO).
AVYA Avaya
$12.58

0.41 (3.37%)

03/11/19
GUGG
03/11/19
INITIATION
Target $22
GUGG
Buy
Avaya initiated with a Buy at Guggenheim
Guggenheim analyst Nandan Amladi started Avaya with a Buy rating and $22 price target. As a newly public company post-bankruptcy, Avaya has emerged with a "much stronger focus" on recurring revenue and an "aggressive" cloud roadmap targeting 25% of total revenue by fiscal 2021, from about 12% today, Amladi tells investors in a research note. He cites the company's combination of a "credible strategic pivot" and an "attractive valuation" for his Buy rating.
03/27/19
BWSF
03/27/19
NO CHANGE
Target $32
BWSF
Strong Buy
Avaya back on investor radars after buyout report, says BWS Financial
A report from Reuters about Avaya (AVYA) possibly being acquired by private equity has put the stock back on investors' radars, BWS Financial analyst Hamed Khorsand tells investors in a research note. He believes the "misunderstanding" of the company's business had "created a significant value gap." The analyst notes, however, that the news report suggests a takeover bid of $20, which is well below his price target of $32. The delta between the reported takeout price and the $32 target is predominately set on how much debt private equity would be willing to put back on Avaya's balance sheet, Khorsand contends. The analyst continues to believe there is "considerable possibility" of Avaya purchasing technology to fill-in its cloud offering. However, that should not prevent a going private bid, says Khorsand. He has a Buy rating on Avaya.
05/10/19
BWSF
05/10/19
NO CHANGE
Target $22
BWSF
Buy
Avaya price target lowered to $22 from $32 at BWS Financial
BWS Financial analyst Hamed Khorsand lowered his price target for Avaya to $22 from $32 saying the company has an "up-hill challenge of regaining investor confidence" following the weaker than expected fiscal Q2 results. Avaya claimed Reuters' story of the company being approached by a third party caused some customers to hold off on hardware and software licenses at the very end of the quarter. Khorsand, however, said he has "never seen this kind of excuse used before and find it difficult to believe." Nonetheless, given the stock's discount to his new price target, the analyst keeps a Buy rating on Avaya.
04/09/19
BWSF
04/09/19
NO CHANGE
Target $32
BWSF
Buy
Avaya could fetch up to $25 from PE buyer, says BWS Financial
Additional news reports about Avaya (AVYA) possibly going private since an initial Reuters report build some credibility about the news, said BWS Financial analyst Hamed Khorsand, who believes Avaya could fetch as much as $25 from a private equity buyer using fiscal 2019 estimates and could be worth as much $30 assuming no improvement in the business for fiscal 2020. He thinks greater synergies could be extracted by a strategic buyer and continues to believe Microsoft (MSFT) would be the best fit as an acquirer. Khorsand keeps a Buy rating and $32 price target on Avaya shares.
EMR Emerson
$60.25

-0.95 (-1.55%)

02/15/19
JPMS
02/15/19
NO CHANGE
Target $77
JPMS
Overweight
JPMorgan's Tusa calls Emerson top 'GARP pick' after investor day
JPMorgan analyst Stephen Tusa says Emerson is his top "GARP pick" after its investor day "reinforced the compelling growth opportunities in these best-in-class franchises." Concerns around a weaker macro environment are overblown, Tusa tells investors in a research note. The analysts is scratching his head as to the stock reaction on management's perceived cautious tone. Emerson's pipeline of project orders at Automation Solutions continues to expand beyond expectations, and now stands at $7.6B, up from ~$6B a year ago, Tusa writes. He keeps an Overweight rating on the shares with a $77 price target.
02/28/19
JPMS
02/28/19
NO CHANGE
JPMS
JPMorgan's Tusa recommends long Emerson, short Rockwell pair trade
JPMorgan analyst Stephen Tusa recommends an automation pair trade of long Emerson (EMR), short Rockwell Automation (ROK). While fundamentals across the automation industry "remain relatively solid for now," the analyst sees potential for "material divergence" between these names as an opportunity, and he favors Emerson. Following the failed bid for Rockwell, Emerson's plans for share gain within marginal discrete markets should allow it to outperform "here from a low base, potentially at the expense" of Rockwell, Tusa tells investors in a research note.
02/06/19
FBCO
02/06/19
NO CHANGE
Target $75
FBCO
Outperform
Emerson price target raised to $75 from $70 at Credit Suisse
Credit Suisse analyst John Walsh raised his price target for Emerson to $75 from $70 saying that despite negative sentiment around upstream O&G CapEx, the company continues to deliver underlying 3-month trailing orders growth in its targeted 5%-10% corridor. The analyst reiterates an Outperform rating on the shares.
04/08/19
SBSH
04/08/19
UPGRADE
Target $81
SBSH
Buy
Emerson upgraded to Buy from Neutral at Citi
Citi analyst Andrew Kaplowtiz upgraded Emerson Electric to Buy from Neutral with an $81 price target.
KEY KeyCorp
$15.97

-0.34 (-2.08%)

03/29/19
03/29/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Wells Fargo (WFC) upgraded to Market Perform from Underperform at Raymond James with analyst David Long saying the retirement of CEO Tim Sloan removes a "headwind." 2. Viacom (VIA, VIAB) upgraded to Buy from Hold at Loop Capital with analyst Alan Gould citing the company's loss of its biggest distributor AT&T (T) having been de-risked which, he believes, raises the likelihood of a Viacom merger with CBS (CBS). 3. F5 Networks (FFIV) upgraded to Neutral from Underweight at Piper Jaffray with analyst James Fish saying after underperforming the tech sector and the market over the last six months by ~20%, some of the main downside share catalysts have played out. 4. Mosaic (MOS) upgraded to Neutral from Underperform at Credit Suisse with analyst Chris Parkinson citing modest downside to Chinese cash operating costs, lower immediate-term ammonia and sulfur costs, evidence of near-term volume discipline, the emphasis on long-term cost reduction programs and balance sheet stability. 5. KeyCorp (KEY) upgraded to Neutral from Reduce at Nomura Instinet with analyst Bill Carcache saying he believes the shares are near a fair valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/06/19
JEFF
05/06/19
NO CHANGE
Target $20
JEFF
Buy
KeyCorp price target raised to $20 from $18.50 at Jefferies
Jefferies analyst Ken Usdin raised his price target for KeyCorp to $20 from $18.50 after traveling with CEO Beth Mooney and CFO Don Kimble. The analyst finds the stock's valuation attractive at nine times 2020 earnings estimates. He looks for a "stronger" Q2 and better estimate stability, especially given the company's $1B share buyback plan. Usdin keeps a Buy rating on KeyCorp.
04/04/19
JPMS
04/04/19
NO CHANGE
JPMS
JPMorgan downgrades Comerica, Zions and KeyCorp, upgrades Signature Bank
In an attempt to reduce interest rate "sensitivity," JPMorgan analyst Steven Alexopoulos downgraded Comerica (CMA), Zions Bancorp (ZION) and KeyCorp (KEY) to Neutral from Overweight and upgraded Signature Bank (SBNY) to Overweight from Neutral. The analyst says his bearish call on the bank sector "remains fully intact" even though the stock are "technically now much cheaper" since his October 2018 call. The tailwinds that helped bottom line growth for banks over the past several years will "fully start transitioning into headwinds" during 2019, Alexopoulos tells investors in a research note. He suggests repositioning portfolios away from asset sensitive banks while simultaneously increasing exposure to liability sensitive banks.
04/04/19
JPMS
04/04/19
DOWNGRADE
Target $17
JPMS
Neutral
KeyCorp downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Steven Alexopoulos downgraded KeyCorp to Neutral from Overweight and lowered his price target for the shares to $17 from $18.
BKS Barnes & Noble
$4.38

0.08 (1.86%)

12/17/18
12/17/18
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Stanley Black & Decker (SWK) upgraded to Buy from Hold at Deutsche Bank with analyst Nicole DeBlase saying she believes the tariffs headwinds facing the company are easing. 2. Calyxt (CLXT) upgraded to Buy from Neutral at Goldman Sachs analyst Adam Samuelson saying the shares are down 42% since his September 7 initiation "despite several positive developments as the company approaches commercialization." 3. Scotts Miracle-Gro (SMG) upgraded to Outperform from Market Perform at Raymond James. 4. Lululemon (LULU) upgraded to Buy from Hold at Stifel with analyst Jim Duffy saying while Lululemon's comps will "inevitably slow against difficult compares," its double-digit revenue growth can continue. 5. Barnes & Noble (BKS) upgraded to Buy from Hold at Craig-Hallum analyst Alex Fuhrman saying initial Q4 checks have indicated improved results, continued cost controls and better holiday sales results, which, combined with the ongoing sales process, should provide "intriguing" upside potential. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/17/18
CHLM
12/17/18
UPGRADE
Target $10
CHLM
Buy
Barnes & Noble upgraded to Buy from Hold at Craig-Hallum
Craig-Hallum analyst Alex Fuhrman upgraded Barnes & Noble to Buy from Hold and raised his price target to $10 from $7. In a research note to investors, the analyst says initial Q4 checks have indicated improved results, continued cost controls and better holiday sales results, which, combined with the ongoing sales process, should provide "intriguing" upside potential.
12/17/18
CHLM
12/17/18
UPGRADE
CHLM
Buy
Barnes & Noble upgraded to Buy from Hold at Craig-Hallum
09/07/18
GABE
09/07/18
UPGRADE
Target $10
GABE
Buy
Barnes & Noble upgraded to Buy from Hold at Gabelli
CBAY CymaBay
$12.09

0.19 (1.60%)

04/15/19
CANT
04/15/19
NO CHANGE
Target $20
CANT
Overweight
Genfit data show CymaBay may be differentiated, says Cantor Fitzgerald
Further competitor primary biliary cholangitis data from Genfit's (GNFTF) elafibranor suggest CymaBay Therapeutics' (CBAY) seladelpar may have a differentiated profile, Cantor Fitzgerald analyst Eliana Merle tells investors in a research note. The analyst keeps an Overweight rating on CymaBay with a $20 price target.
02/22/19
LEER
02/22/19
INITIATION
Target $22
LEER
Outperform
CymaBay initiated with an Outperform at SVB Leerink
SVP Leerink analyst Pasha Sarraf initiated CymaBay with an Outperform rating and $22 price target, telling investors in a research note that the company is demonstrating "impressive" efficacy and safety profile in PBC and pre-clinically in NASH. Sarraf says he is positive on the immunology sector with its diverse indications, continuous innovation, and deep expertise, and is looking long for opportunities in challenging immuno-metabolism and metabolism sectors, in areas like NASH, obesity and diabetes.
03/01/19
PIPR
03/01/19
NO CHANGE
Target $30
PIPR
Overweight
Piper Jaffray loves the setup for CymaBay shares into NASH data
CymaBay's Seladelpar has made "tremendous progress" in primary biliary cholangitis over the past year its competitive positioning continues to improve, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. Further, the analyst believes the drug's nonalcoholic steatohepatitis opportunity is not currently being factored into the existing valuation. The analyst expects to receive topline data from the ongoing Phase IIb trial of seladelpar in NASH next quarter. If successful, it could "multiply" the $750M PBC opportunity in his model, Van Buren says in a research note titled "We Love The Setup Of CBAY Here; Reiterate The Overweight." He keeps a $30 price target on CymaBay shares.
05/14/19
SBSH
05/14/19
INITIATION
Target $21
SBSH
Buy
CymaBay initiated with a Buy at Citi
Citi analyst Joel Beatty started CymaBay Therapeutics (CBAY) with a Buy rating and $21 price target. The analyst believes the company's seladelpar will "likely dethrone" Intercept Pharmaceuticals' (ICPT) Ocaliva as the top-selling branded primary biliary cholangitis drug. Topline results for seladelpar in PBC are anticipated in 2021 and the analyst sees a 75% probability of approval.

TODAY'S FREE FLY STORIES

PUMP

ProPetro Holding

$8.85

0.245 (2.85%)

14:35
10/18/19
10/18
14:35
10/18/19
14:35
Periodicals
ProPetro Holding under investigation by SEC, Reuters says »

The SEC is probing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NLY

Annaly Capital

$8.77

0.1 (1.15%)

, IVZ

Invesco

$15.76

0.12 (0.77%)

14:26
10/18/19
10/18
14:26
10/18/19
14:26
Hot Stocks
Annaly Capital, Invesco named as stock picks by Bill Gross »

Bill Gross, during an…

NLY

Annaly Capital

$8.77

0.1 (1.15%)

IVZ

Invesco

$15.76

0.12 (0.77%)

D

Dominion

$82.18

-0.2 (-0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 31

    Oct

  • 01

    Nov

  • 10

    Nov

  • 10

    Nov

  • 12

    Nov

BCS

Barclays

$8.49

0.12 (1.43%)

14:25
10/18/19
10/18
14:25
10/18/19
14:25
Options
Barclays call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 27

    Oct

  • 12

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
10/18/19
10/18
14:17
10/18/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
10/18/19
10/18
14:16
10/18/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FANG

Diamondback Energy

$82.71

-1.42 (-1.69%)

14:15
10/18/19
10/18
14:15
10/18/19
14:15
Options
Diamondback Energy put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

QQQ

Invesco QQQ Trust

$192.00

-1.56 (-0.81%)

, SPY

SPDR S&P 500 ETF Trust

$298.50

-0.74 (-0.25%)

14:13
10/18/19
10/18
14:13
10/18/19
14:13
Technical Analysis
On The Fly: ETF fund flow highlights »

For the week creations…

QQQ

Invesco QQQ Trust

$192.00

-1.56 (-0.81%)

SPY

SPDR S&P 500 ETF Trust

$298.50

-0.74 (-0.25%)

IWM

iShares Trust Russell 2000 Index Fund

$152.78

-0.56 (-0.37%)

XLU

Utilities SPDR

$63.76

0.16 (0.25%)

IVV

iShares Core S&P 500

$300.17

-0.76 (-0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XEC

Cimarex Energy

$42.31

-0.36 (-0.84%)

14:05
10/18/19
10/18
14:05
10/18/19
14:05
Options
Cimarex Energy call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

SPXC

SPX Corporation

$40.48

0.265 (0.66%)

13:58
10/18/19
10/18
13:58
10/18/19
13:58
Initiation
SPX Corporation initiated  »

SPX Corporation initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 20

    Nov

  • 20

    Nov

  • 21

    Nov

  • 21

    Nov

WE

We Company

$0.00

(0.00%)

, JPM

JPMorgan

$120.80

0.41 (0.34%)

13:58
10/18/19
10/18
13:58
10/18/19
13:58
Periodicals
SoftBank, JPMorgan submit competing rescue packages for WeWork, FT says »

SoftBank (SFTBF) and…

WE

We Company

$0.00

(0.00%)

JPM

JPMorgan

$120.80

0.41 (0.34%)

SFTBF

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 27

    Oct

  • 04

    Nov

  • 21

    Nov

  • 14

    Jan

13:55
10/18/19
10/18
13:55
10/18/19
13:55
General news
Action Economics Survey results: »

Action Economics Survey…

JNJ

Johnson & Johnson

$129.11

-7.09 (-5.21%)

13:48
10/18/19
10/18
13:48
10/18/19
13:48
Recommendations
Johnson & Johnson analyst commentary  »

Credit Suisse says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 07

    Dec

DIS

Disney

$131.17

-1.2 (-0.91%)

, SNE

Sony

$58.86

-1.195 (-1.99%)

13:47
10/18/19
10/18
13:47
10/18/19
13:47
On The Fly
Box Office Battle: 'Maleficent,' 'Zombieland' sequels hit theaters »

Welcome to "Box Office…

DIS

Disney

$131.17

-1.2 (-0.91%)

SNE

Sony

$58.86

-1.195 (-1.99%)

T

AT&T

$38.09

0.27 (0.71%)

VIA

Viacom

$25.00

-0.6 (-2.34%)

VIAB

Viacom

$22.24

-0.37 (-1.64%)

CMCSA

Comcast

$45.49

-0.45 (-0.98%)

CMCSK

Comcast

$0.00

(0.00%)

LGF.A

Lionsgate

$8.50

-0.1 (-1.16%)

LGF.B

Lionsgate

$8.00

-0.07 (-0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 07

    Nov

  • 07

    Nov

  • 07

    Nov

  • 14

    Nov

  • 14

    Nov

  • 18

    Nov

  • 19

    Nov

MAS

Masco

$43.82

0.18 (0.41%)

13:45
10/18/19
10/18
13:45
10/18/19
13:45
Options
Masco call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

IGT

International Game

$13.15

-0.25 (-1.87%)

13:25
10/18/19
10/18
13:25
10/18/19
13:25
Options
International Game call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:25
10/18/19
10/18
13:25
10/18/19
13:25
General news
Wall Street is taking a hit on a couple of news items »

Wall Street is taking a…

13:25
10/18/19
10/18
13:25
10/18/19
13:25
Conference/Events
JPMorgan autos/auto parts analyst to hold an analyst/industry conference call »

Autos & Auto Parts…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
10/18/19
10/18
13:17
10/18/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
10/18/19
10/18
13:16
10/18/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GGAL

Grupo Financiero

$12.45

-0.05 (-0.40%)

13:15
10/18/19
10/18
13:15
10/18/19
13:15
Options
Grupo Financiero put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NWBO

Northwest Biotherapeutics

$0.00

(0.00%)

13:12
10/18/19
10/18
13:12
10/18/19
13:12
Syndicate
Breaking Syndicate news story on Northwest Biotherapeutics »

Northwest Biotherapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

BA

Boeing

$355.77

-13.36 (-3.62%)

13:12
10/18/19
10/18
13:12
10/18/19
13:12
Periodicals
Boeing pilot said he 'lied' to FAA in texts to colleague, NY Times reports »

Mark Forkner, a Boeing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

MAT

Mattel

$11.18

0.07 (0.63%)

13:06
10/18/19
10/18
13:06
10/18/19
13:06
Recommendations
Mattel analyst commentary  »

Jefferies sees increased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

13:05
10/18/19
10/18
13:05
10/18/19
13:05
General news
Baker-Hughes Rig Count N. Amer. data reported »

Week of 10/18…

FEYE

FireEye

$15.06

-0.06 (-0.40%)

13:05
10/18/19
10/18
13:05
10/18/19
13:05
Options
FireEye call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.